Aleafia Health Inc Stock Forecast, "ALEAF" Stock ...

I'm doing a tribute to the 24 days of Christmas by going over the financial statements of 24 companies that are considered downrange, speculative, and just plain high risk.
The legal cannabis industry already has a ton of risk in it - but this stuff - is only for thrill seekers. All opinions are my own, and certainly not a recommendation for or against any of them, or to buy or sell.
I've limited myself to 45mins to each, and kept to most recent financial statements You'll likely know more about the company than me if you're following them. This is only my reactions with a brief commentary about what I see in their financial statements.
I haven't been consistent in following them all over the past year: some I have, others not.
The second one of this year.....is here
~~CMM - Canabo Medical Inc.~~
Scratched! Guess there’s another slot open for a Dive in this year’s Crawl! I did take a run at Aleafia’s financials a few weeks ago though. Their ‘merger’ with Emblem hadn’t yet been announced. Alefia ‘Just Said No’ to cultivation by the looks of it. Best choice for them, at least on the face of it.
ISOL - Isodiol International
Price Then: $11.50 Price Now: $1.71

Has taken cash and turned it into receivables, inventory, prepaids, and fixed assets. Looking good here.
Except for the $110MM added in goodwill/intangibles. Entrance fee to explore the world of LATAM and vape pens I suppose.
Significant inventory build. 50% margin YTD.
That 50% margin - of $9MM YTD, is supporting $21MM of operating expenses over same period.
Wages and salaries have exploded. As has SBC (which has eclipsed it no less for last period).
As has advertising and promotions. Doesn’t bode well for margin maintenance
Professional fees same. ‘Detonated’ applies as an appropriate adjective as well.
Intangibles/goodwill now 76% of all assets. Up 10%. Less than the rest of G&A is a good thing?
Per Note 19, of the $143MM in these as Canadian assets, they have $0 in revenue attached.
US/UK - far better. Provided that goodwill can be leveraged somewhere…..
Kure Corp eye watering in cost. Hella price to pay for a vape manufacturer. $36MM cash too. Sellers weren’t taking (rolling) paper.
Share price blast radius is notable.

Well then. International operations do attract cost (their G&A is bracing), as does business dev. Especially in Brazil. When a company with a net book value of $2.7MM costs $36MM (takes me back to Canopy buying 2 money losing greenhouses with a net book value of $6MM for $86MM at the time).
ISOL’s still shopping too. Round Mountain looks like ISOL tossed them a life preserver. One will have to trust mgmt as to quality/fit of underlying assets. I didn’t detail, it’s only a half million, they bought it for what looks like working capital, I assume it saved them from insolvency.
A pretty sweeping and broad horizon is presented by these statements - in a company looking internationally. They’ve got a clean professional presence (I’ve seen them at pretty much every trade show I’ve attended), yet, $12MM in op costs per quarter based on $8MM in sales for same….sheesh.
Margin relatively static as well. That needs to improve, and sales need to triple+ to support ops. They lost $6MM per quarter this year, sales modestly up Q over Q.
IMH - Invictus MD
Price Then: $1.40 Price Now: $0.81

Cash in pocket. Considering burn (building $15MM, AbLab $10MM), it’s holding.
Salaries at $2.5MM, professional fees $1.5MM. To the latter, these have been abating as companies get up and planing. Not here.
Op expenses high, $13MM this quarter. Ouch.
Margin seems erratic. Might be operational stabilization, might be a very dark cloud.
Note 15 explains where their cash came from, along with a 40% increase in shares o/s
Warrant strike prices are all over the map. Relatively modest in options. Despite $2.5MM in SBC this quarter, don’t look like it’s going to be as high for awhile. I’d need more time to confirm that.
Related party transactions…sigh. Compelling business reasons are great. Anything less....more than simply poor optics. Can’t tell either way, in any of these without going deep. Note 16.
Getting a rock star as a front end ain’t cheap. Added $7MM in goodwill, from an $11MM spend. Remainder was expensed in sales and marketing. Well then. Note 10.
Note 11 - ran out of time.

Few things here. While I don’t get the warm and fuzzies from this (what the elves are taking these days apparently does give you that & they swear by it), it looks better than it did last year. I have concerns over sales, margins, and the assets in subs. Wrote one off this year. Only 9 months to find out it’s a mutt? Honestly, this company requires far (far) more time to get a handle on. Will do on website. Needs a full once over to be fair.
MDM - Marapharm Ventures (now: LIHT CANNABIS)
Price Then: $0.92 Price Now: $0.17

50% of assets goodwill. Full Spectrum indeed. Better be some good gear.
70MM warrants o/s
Shares were issued for 2018 include (clears throat): cash; assets; services; debt; warrant execution; stock options; bond bonus; RSU’s; and even some for the treasury. Whew! Note 14
The 10MM warrants issued at $0.20 look like playing catchup. Share price dump has been….unhelpful in that regard.
Revenues anemic, laying missionary on 30% margins. Blech.
Wrote a gain on a ‘bargain purchase price’ regarding Full Spectrum. Sheesh. After booking the rest as goodwill?
Would show heavy losses if it wasn’t for that $7MM up write.
Good disclosure on commitments (Note 16). And in segmented reporting (Note 17).
Note 21 (subsequent events) is busy. Operationalizing the US.

Sigh. Another that needs more time. Where is Quadron when you need them?
Nothing stand out - at least in terms of company differentiation or size. Boring. And leveraged. The Full Spectrum thingy hits their financials like landing an 8 ft fish in a 7 ft boat. I’d need to deconstruct that ‘asset’ to get any strong utility out of this. I’d really want to have a handle on it - and management - if I was to go anywhere near this outfit. Doesn’t look unfairly priced. Unless you ask the people who placed at $0.865, $0.70, and $0.50 during the year.
Ugliest thing I see is them issuing shares for $0.38 and $0.04 to retire debts, when the share price was $0.80 and $0.40 respectively. If I was one of those in the private placements, I’d be coming out of my shoes on that (Note 14). Even if it was only $40k. Speaks to quiet desperation at one point.
Whether there’s a viable business in here….tune in next time for another episode of ‘Dive Bar Pub Crawl’. As I see it….this would take far too much time for the level of interest I have in it. Unless Full Spectrum is a home run…..
ATT - Abattis Biocuetical Corp.
Price Then: $0.48 Price Now: $0.08
Man, what a difference a year makes. I’ve largely avoided looking over last years’ Crawl as reference, except to skim for major points. This one remains clear in my memory…it looked like a complete mutt then. Only thing they looked good at was producing press releases. They’re still kicking, as is the rate of news releases/month. They have begun paying a formal IR front end, so maybe this will slow down. Or perhaps speed up. Can’t tell. Ah well, latest fins I can find are somewhat old (Sept release. Amended too :( ). New ones should be due pretty quick.

Sales in first quarter of this year: $237.00. Yep, that’s dollars.
Expenses: $6.9MM same quarter. $3.3MM in consulting fees alone.
Note 13 details the consulting fees. The note is also titled ‘Related Party Transactions’.
Share float increased from 159MM to 406MM YoY. There are no words for this.
Net loss for year end, $24MM on $5,900 in sales. There are fewer than no words for this. Like, an empty set of words.
Well, at least there’s $1.3MM in PP&E. Woot!
And….$51MM in intangibles.
And….$10MM in blockchain, via investment in some sort of clearinghouse to provide liquidity for the crypto-tokens they’ve invented (some sort of Active Health/CanNUMUS spit swap).
* “Token burning will also act as a low‐friction method of returning value to token holders”.* Well, there you go. You can rich, and be frictionless whilst doing so (Note 7).

Gonna stop there. I’ve got a stitch in my side, and a headache. If I ever get my hands on the mug who suggested this one….the elves heads are collectively a ‘bag of cats’, and the little buggers staged a walkout. They’re outside singing Woody Guthrie songs and burning pallets. This totally sucks. As does Abattis’ financials.
They offer low friction on tokens perhaps, but any cash put toward this thing will probably have the friction of a canvas bag re-entering the atmosphere. Poof. My personal choice for ‘Dive Bar of the Year’. Curiously, it’s not an easy title to take.
IN - Inmed Pharmacuetical
Price Then: $1.47 Price Now: $0.37

Plenty of cash. Not much change in assets, or anything else for that matter over the year.
Expenses flat, R&D up, as is SBC. Nothing earth-shaking
Easy to look at from B/S - Income Statement perspective. Loving pharma co’s in this regard.
Active in placements. Steady amount of funds coming in, even if down-raising. Shows interest.
50MM in options and warrants o/s. Share price trajectory has taken a lot of them out of play for the moment.
R&D expenses mainly salaries, nominal amount to patents.
In pharma, investors need to have a handle on viability of the research, quality of the management, etc. doing these is kinda fun as the financials are a dream compared to… oh….an ‘Abattis’ let’s say.

TGIF - Friday Night Inc.
Price Then: $1.20 Price Now: $0.37
I looked at these guys as recently as July. I also met up with them at MJBizCon in Vegas. I asked for a look at their facility….they never did get back to me. I won a laptop bag and some nice swag at the booth on a business card ‘draw’, it didn’t help getting a tour tho. I really wanted to see it…the financials got me curious in last year’s Crawl, and I strongly get the sense I’m missing something of note in them. Seems an incomplete story tbh. Maybe just some mild indigestion.
And….for a region notorious for $70 eights in top shelf, I was also curious why they were recording sub $5 revenue on grams. Got the annuals now….

$6MM in gross margin, $11MM in expenses. Ramping.
Forex and translation (assuming Fx) $1.1MM. A correction, or, an acquisition conversion to native currency.
Modest forecast for sales price per gram ($4.16). I really want to know why their sales price sucks this hard. Outside of scope for the Crawl (time, and, I need an answer from the company. Guys?)
Good disclosure largely, Notes 8, 7, and 11
Writing up forex accretion on goodwill, ptooey.
Still 22MM of in-the-money warrants and options. ~=$4MM live.
Marginal adjustments to cap structure through secured lending. Marginal though.
Related party transactions relatively good compared to peerset.
More good disclosure in segmentation (Note 19).

There’s a reason price softening is lower in this one compared to others - at least they are in production & they have a product suite (at least in their booth at MJBizCon). No retail frontage (?) would explain the shitty sales price. I have somewhat of a soft spot for Canadian business, and I’d hope that relatively early movers would be seeing this start to ramp.
As my trip to the US revealed - the US is a hyper-competitive compartmentalized environment. I do believe vertical integration is requisite for a company with this breadth and spend.
Gonna sit in on the next call on these guys, and try and get a (the) story. Looks like false starts in build out, and challenges ramping. Sales are growing. They don’t look to be peddling a ’take me out’ story or stance…but….I have blind spots on this one.
Because of Abattis, the elves are now wearing balaclavas and carrying home-made gas masks. Told me they are going for a stroll. I gave the RCMP a heads up. Gotta keep up good community relations and all.

aleafia health inc stock forecast video

Close price at the end of the last trading day (Tuesday, 9th Feb 2021) of the ALEAF stock was $0.86. This is 17.67% more than the trading day before Monday, 8th Feb 2021. During the day the stock fluctuated 29.27% from a day low at $0.70 to a day high of $0.90. Aphria Stock Forecast 2025 / Aleafia Health Inc Stock Could Soon Be Set To Soar Higher / Whether you call it hemp, cannabis, herb, pot, or marijuana, this industry has the potential to generate.. The average aphria stock price for the last 52 weeks is 4.34. Stock price forecast for apha: A summary of key financial strength and profitability metrics. Closes accretive, strategic acquisition of ... Aleafia Health Inc is a vertically integrated cannabis health and wellness company which owns three cannabis product and cultivation facilities where it produces a diverse portfolio of commercially high-margin derivative products including oils, capsules and sprays. The company operates national network of medical cannabis clinics and has seen over 60,000 patients to date. Aleafia Health Inc Stock Price Forecast, "ALEAF" Predictons for2021 Aleafia Health Inc is a vertically integrated cannabis health and wellness company which owns three cannabis product and cultivation facilities where it produces a diverse portfolio of commercially high-margin derivative products including oils, capsules and sprays. The company operates national network of medical cannabis clinics and has seen over 60,000 patients to date. Real time Aleafia Health Inc (ALEAF) stock price quote, stock graph, news & analysis. Latest Stock Picks Investing Basics Premium Services. Return. S&P. Stock Advisor Flagship service. 604%. 121% ... How is Aleafia Health forecast to perform in the next 1 to 3 years based on estimates from 3 analysts? 116.9%. Forecasted annual earnings growth . Earnings and Revenue Growth Forecasts. Analyst Future Growth Forecasts. Earnings vs Savings Rate: AH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%). Earnings vs Market: AH is ... As of 2021 February 10, Wednesday current price of ALEAF stock is 0.730$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). Aleafia Health Inc has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. Aleafia Health Inc. operates as an integrated cannabis health and wellness company. It produces a portfolio of products, including dried flower and pre-rolls, as well as oil drops and capsules, and oral sprays. The company offers its products under the Emblem and Symbl brands. It also operates a network of 25 medical cannabis clinics; and education centers. Aleafia Health Inc. is headquartered ... Aleafia Health has been named the TMX Group’s 2019 TSX Venture 50 top performing company of the year amongst all 2,000 TSX Venture Exchange listed companies. The award was based on three equally weighted criteria, market capitalization growth, share price appreciated and trading volume. This is the first time a cannabis company has achieved top performing status. Honours

aleafia health inc stock forecast top

Cannabis Stock Market News June 6 2019 - Aleafia, Harvest One, Pasha Brands, Green Thumb Industries

Aleafia Health Inc (CVE:ALEF) Graduation to TSX & Emblem Corp (CVE:EMC) Agreement - Duration: 9:34. Midas Letter RAW 1,516 views 🔴 Watch Day Trading Live - May 27, NYSE & NASDAQ Stocks (Live Stream) Stock Market Today by TraderTV Live 2,866 watching Live now Dr. Gabor Maté - Cannabis and Addiction - Duration: 1:05:05. Aleafia Health Inc (CVE:ALEF) (OTCMKTS:ALEAF) (FRA:ARAH) CFO Benjamin Ferdinand discusses the major upcoming catalysts for the company. Aleafia was recently ... This video is unavailable. Watch Queue Queue. Watch Queue Queue 26:31 - Aleafia Health Inc (CVE:ALEF) (OTCMKTS:ALEAF) (FRA:ARAH) CEO Geoff Benic shares details from the company’s latest financial statement. Aleafia received approval to begin going outdoors ... Julian Fantino, Chairman, alongside Geoffrey Benic, CEO, Aleafia Health Inc. (ALEF), joined Rob Peterman, Vice-President, Global Business Development, Toront... It's week 11 at our historic Port Perry Outdoor Grow facility. The plants are flowering and we're getting close to harvest time. Let's keep growing together. Aleafia Health Inc (CVE:ALEF) (OTCMKTS:ALEAF) (FRA:ARAH) CEO Geoffrey Benic shares details about the company’s 22 cannabis medical clinics, which serve 50,00... Aleafia Health Inc (CVE:ALEF) (OTCMKTS:ALEAF) (FRA:ARAH) CEO Geoffrey Benic shares details of the company’s 2019 plans. Aleafia is nearing completion of Phas... "The truth about mobile phone and wireless radiation" -- Dr Devra Davis - Duration: 1:01:30. The University of Melbourne Recommended for you

Aleafia Health Inc Stock Forecast, "ALEAF" Stock ...